Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

Lakewood-Amedex Biotherapeutics (LABT) will present at the H.C.

(Very High)

(Neutral)

Rhea-AI Summary

Lakewood-Amedex Biotherapeutics (LABT) will present at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026, in New York City.

CEO Kelvin Cooper, Ph.D., will deliver a virtual presentation on the company’s Bisphosphocin® antimicrobial platform. During the conference, he will also hold one-on-one meetings with registered investors and potential partners to discuss the company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

09/08/2026 - 08:02 AM

SARASOTA, Fla., Sept. 8, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin^® class, today announced that Kelvin Cooper, Ph.D., CEO of Lakewood-Amedex Biotherapeutics will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference, which is being held September 14-16, 2026, in New York City.

Details of the presentation are as follows:

Event:	H.C. Wainwright 28th Annual Global Investment Conference
Date:	September 14-16, 2026

During the conference, Dr. Cooper will conduct one-on-one meetings with registered investors and potential partners, showcasing the company's business and clinical development strategy, recent corporate achievements, and anticipated milestones.

About Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin^® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.

Contact

Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com

Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
cmcdonald@tiberend.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/lakewood-amedex-biotherapeutics-to-present-at-hc-wainwright-28th-annual-global-investment-conference-302872149.html